GENGLYCOS
Live / Applied — Fourth extension granted (statement of use) (as of 01 Oct 2025)
What this means for you
Not registered yet, but its 03 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97822923
- Mark type
- Stylized text
- Filed
- 03 Mar 2023
- Published for opposition
- 28 Nov 2023
- Attorney of record
- Brian Focarino
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of metabolic and rare metabolic and genetic diseases and disorders; gene therapy products for the treatment of metabolic and rare diseases and disorders, namely, virus vector-based gene therapies for intravenous delivery
- Class 042 — Scientific and technological services: Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, and metabolic and rare metabolic and genetic diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; pharmaceutical, scientific, and medical research, namely, compiling and sharing of patient data for research purposes in the field of metabolic and rare metabolic and genetic diseases and disorders; providing medical and scientific research information in the field of metabolic and rare metabolic and genetic diseases and disorders
- Class 044 — Medical, beauty and agricultural services: Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of metabolic and rare metabolic and genetic diseases and disorders
Owner
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
Prosecution history
- 02 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2025 — SOU EXTENSION 4 GRANTED
- 01 Oct 2025 — SOU EXTENSION 4 FILED
- 01 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Jun 2025 — SOU EXTENSION 3 GRANTED
- 18 Jun 2025 — SOU EXTENSION 3 FILED
- 18 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Dec 2024 — SOU EXTENSION 2 GRANTED
- 17 Dec 2024 — SOU EXTENSION 2 FILED
- 17 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 02 Aug 2024 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 02 Aug 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 02 Aug 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED